NEWS

San Jose, CA – December 2, 2022 (PRESS RELEASE)

Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”) presented Phase 2A clinical results of NA-831, and the proposed Phase 3 clinical proptol of NA-831 at the Clinical Trials of Alzheimer's Disease (CTAD) International Conference, November 31 to Devember 2, 2022, San Francisco, California, United States.

Title: “Proposing the neurogenesis hypothesis for Alzheimer’s disease with a case study- phase 2 clinical trials of NA-831”
Authors: Lloyd Tran, and Markku Kurkinen

Title: “A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer's Disease”
Authors: Lloyd Tran, Fern Vu and Markku Kurkinen

At the AAIC 2022, Lloyd Tran, the Chairman and CSO of Biomed presented the Neurogenesis Hypothesis for Alzheimer’s (NHA) and the results of the clinical trial Phase 2A of NA-831 that supports the hypothesis. This was the first time that the Neurogenesis Hypothesis for Alzheimer has been presented with supported clinical data at the CTAD International Conference.
The hypothesis can be summarized as below:

* The hippocampus is critical for learning and memory.
* The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN).
* There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals.
* AHN impairment compromises hippocampal function in AD and MCI.
* This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease.
* Therefore, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.

Alzheimer’s Disease is a progressive and irreversible neurodegenerative disorder that affects millions of people worldwide. Today, more than 5.8 million people in the United States and 45 million people worldwide live with Alzheimer’s. There is currently no cure, no prevention and no treatment of Alzheimer’s disease.

The study was a randomized, double-blind, placebo-controlled parallel-group Phase 2A clinical study of NA-831, conducted in patients with mild cognitive impairment (MCI), and patients with mild and moderate Alzheimer’s disease over 24 weeks, with a follow-up for an additional 24 weeks. In addition to the primary safety objective, the study assessed the efficacy in terms of clinical symptoms, which were exploratory objectives in this study.

In an early stage of Alzheimer's disease (“mild Alzheimer’s) a person may function independently and can still drive, work and be part of social activities. Moderate Alzheimer's is typically the longest stage and can last for many years. During the moderate stage of Alzheimer’s, the dementia symptoms are more pronounced. As the disease progresses, the person with Alzheimer's will require a greater level of care.

NA-831™is a small drug molecule that exhibits neuroprotection, i.e. can prevent or slow disease progression by halting or at least slowing the loss of neurons. The drug also exhibits neurogenesis, and cognitive protective properties across a range of disease models. Neurogenesis is the process by which new neurons are generated from neural stem cells in the adult. Neurogenesis is reported to play a role in learning, memory and cognitive functions.

NA-831™ has been shown to be safe and well tolerated in healthy volunteers.

The results suggest that NA-831 could slow decline in cognitive function of patients with MCI due to Alzheimer’s disease, or mild to moderate dementia due to Alzheimer’s disease.

NA-831 was well-tolerated at 30 mg per day administered orally. There were no serious adverse events.

This press release discusses investigational uses of agents in development.

About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

- CONTACT:

Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com